Synta, the Lexington, MA-based developer of cancer drugs, said today it has completed enrolling 630 patients in a clinical trial of its lead product candidate for melanoma that has spread through the body. The company (NASDAQ: [[ticker:SNTA]]) has a goal of releasing results from the study in May. We profiled Synta’s efforts to develop this drug, elesclomol, last month.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
